BKM120
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Prostate Cancer
Conditions
High Risk Prostate Cancer
Trial Timeline
Apr 23, 2013 → Feb 5, 2015
NCT ID
NCT01695473About BKM120
BKM120 is a phase 2 stage product being developed by Novartis for High Risk Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01695473. Target conditions include High Risk Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01613677 | Phase 2 | Withdrawn |
| NCT02220855 | Phase 2 | Completed |
| NCT01550380 | Phase 2 | Withdrawn |
| NCT01695473 | Phase 2 | Terminated |
| NCT02128724 | Phase 1 | Completed |
| NCT01833169 | Phase 2 | Completed |
| NCT01513356 | Phase 1 | Completed |
| NCT01626209 | Phase 1 | Completed |
| NCT01396499 | Phase 1 | Completed |
| NCT01629615 | Phase 2 | Completed |
| NCT01501604 | Phase 2 | Withdrawn |
| NCT01727128 | Phase 1 | Completed |
| NCT01339052 | Phase 2 | Completed |
| NCT01385293 | Phase 2 | Terminated |
| NCT01297491 | Phase 2 | Completed |
| NCT01289041 | Phase 2 | Completed |
| NCT01283503 | Phase 1 | Completed |
| NCT01068483 | Phase 1 | Completed |
Competing Products
20 competing products in High Risk Prostate Cancer